FOR IMMEDIATE RELEASE

MEDIA CONTACT:
Farzana Azam
Executive Director, Global Marketing
+1 (647) 261 3628
media.inquiries@celerion.com

Celerion Selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium for The Beta Cell Project.

(Lincoln, NE; Jun 11, 2014) – Celerion is pleased to announce it has been selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to provide clinical support for The Beta Cell Project. The Beta Cell Project is a program of studies designed to standardize biomarker measures of beta cell function. Celerion will provide clinical recruitment and conduct to support The Beta Cell Project and assist the FNIH in developing pharmacodynamic measures of beta cell function, with the goal to create industry standards.

The Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH that endeavors to discover, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics. The consortium is helping create a new era of personalized medicine, with more highly predictive markers that have an impact during a patient's illness or lifespan. Their goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.

"Celerion has continued to invest in and expand our capabilities in metabolic disease to support early Proof-of-Concept studies in the development of diabetes, obesity, metabolic and cardio-metabolic interventions. We are therefore delighted to have been selected to support programs by the FNIH in the area of metabolic disorders," said Philip Bach, Vice President of Global Clinical Research at Celerion. "The award of this program, and knowing that our contribution will help set industry standards, is recognition of our expertise in this area and the quality of data delivered to clients."

About Celerion

Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.

With over 40 years of experience and 750 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical Proof-of-Concept, Cardiac Safety Services (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion's service offerings. For more information please visit www.celerion.com.